Galectin Therapeutics reported $27.65M in Assets for its fiscal quarter ending in June of 2024.





Assets Change Date
AbbVie USD 147.68B 12.57B Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Galectin Therapeutics USD 27.65M 1.76M Jun/2024
Gilead Sciences USD 51.41B 2.05B Sep/2026
Immunic USD 136.42M 22.75M Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Merck USD 132.77B 2.97B Sep/2026